Bristol-Myers Squibb Company (FRA:BRM)

Germany flag Germany · Delayed Price · Currency is EUR
37.06
-0.31 (-0.83%)
Last updated: Oct 17, 2025, 5:26 PM CET
-0.83%
Market Cap78.07B
Revenue (ttm)40.62B
Net Income (ttm)4.30B
Shares Outn/a
EPS (ttm)2.12
PE Ratio18.16
Forward PE7.02
Dividend2.22 (5.99%)
Ex-Dividend DateOct 3, 2025
Volume1,716
Average Volume712
Open37.08
Previous Close37.37
Day's Range36.81 - 37.27
52-Week Range37.00 - 58.51
Betan/a
RSI47.64
Earnings DateOct 30, 2025

About FRA:BRM

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company’s products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Opdivo for various anti-cancer indications; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthrit... [Read more]

Industry Pharmaceutical Preparations
Founded 1887
Employees 34,100
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol BRM
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

News

Validea Detailed Fundamental Analysis - BMY

Below is Validea's guru fundamental report for BRISTOL-MYERS SQUIBB CO (BMY). Of the 22 guru strategies we follow, BMY rates highest using our Earnings Yield Investor model based on the published stra...

4 days ago - Nasdaq

Bristol Myers (BMY) Reports Positive Trial Data on Cancer Drug

Bristol Myers (BMY) Reports Positive Trial Data on Cancer Drug

4 days ago - GuruFocus

Bristol Myers Squibb (BMY) Reports Promising Phase I Trial Results for Iza-bren

Bristol Myers Squibb (BMY) Reports Promising Phase I Trial Results for Iza-bren

4 days ago - GuruFocus

HopeHealth Launches Phase 3 Clinical Trial Site To Advance Lupus Research With Support From Bristol Myers Squibb

First HopeHealth Clinical Trial Marks Major Milestone for Access to Medical Research in Rural South CarolinaOriginally published on HopeHealth NORTHAMPTON, MA / ACCESS Newswire / October 16, 2025 / Ho...

5 days ago - Wallstreet:Online

BMY Factor-Based Stock Analysis

Below is Validea's guru fundamental report for BRISTOL-MYERS SQUIBB CO (BMY). Of the 22 guru strategies we follow, BMY rates highest using our Earnings Yield Investor model based on the published stra...

6 days ago - Nasdaq

BMY Slips Below 50-Day SMA: Buy, Sell or Hold the Stock?

Bristol Myers stock slips below its 50-day average as generic pressure, high debt, and trimmed earnings outlook weigh on sentiment

7 days ago - Nasdaq

Every Word Matters: The Next Chapter of Our Universal Patient Language

Originally published on BMS.com in recognition of Health Literacy Month, the following article highlights how Bristol Myers Squibb's Universal Patient Language (UPL) program is advancing clearer, more...

7 days ago - Wallstreet:Online

Will the Orbital Acquisition Strengthen BMY's Cell Therapy Portfolio?

Bristol Myers' $1.5B buyout of Orbital Therapeutics expands its cell therapy reach with a next-gen in vivo CAR T candidate and advanced RNA platform.

8 days ago - Nasdaq

Bristol Myers Squibb to Present Data at ESMO 2025 Showcasing Progress of Oncology Portfolio Across Diverse Tumor Types

Bristol Myers Squibb (NYSE: BMY) today announced the presentation of data across its oncology portfolio and pipeline at the European Society for Medical Oncology (ESMO) Congress 2025 to be held from O...

8 days ago - Wallstreet:Online

Notable healthcare headlines for the week: Novo Nordisk, Bristol Myers Squibb and J&J in focus

Get the latest on healthcare stocks, major acquisitions, legal cases, and policy updates impacting the market.

10 days ago - Seeking Alpha

Key deals this week: Protagonist Therapeutics, Bristol Myers, Novo Nordisk, Fifth Third Bancorp and more

Stay updated on major M&A deals across biotech, fintech, and energy sectors this week. Discover key market moves and their impact.

10 days ago - Seeking Alpha

Bristol-Myers Squibb (BMY) Expands Cell Therapy Portfolio with $1.5 Billion Acquisition

Bristol-Myers Squibb (BMY) Expands Cell Therapy Portfolio with $1.5 Billion Acquisition

11 days ago - GuruFocus

Bristol Myers Squibb (BMY) Expands with Orbital Therapeutics Acquisition

Bristol Myers Squibb (BMY) Expands with Orbital Therapeutics Acquisition

11 days ago - GuruFocus

Bristol Myers (BMY) to Acquire Orbital Therapeutics in $1.5 Billion Deal

Bristol Myers (BMY) to Acquire Orbital Therapeutics in $1.5 Billion Deal

11 days ago - GuruFocus

Bristol-Myers buys Orbital Therapeutics for $1.5 billion

Drugmaker Bristol-Myers Squibb said on Friday it will acquire privately held cell therapy developer Orbital Therapeutics for $1.5 billion in cash.

11 days ago - CNBC

Bristol Myers Squibb and National Community Pharmacists Association Pilot Rural Heart Health Care Initiatives

BMS and NCPA to address cardiovascular disease and enhance patient care coordination with specialized training in rural Alabama, Arkansas, Kentucky, Louisiana, Mississippi, and Missouri pharmaciesOrig...

11 days ago - Wallstreet:Online

BMY November 28th Options Begin Trading

Investors in Bristol Myers Squibb Co. (Symbol: BMY) saw new options begin trading today, for the November 28th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the B...

12 days ago - Nasdaq

Can BMYs Neuroscience Portfolio Help to Diversify Its Business?

Bristol Myers gains FDA Fast Track status for its Alzheimer's antibody BMS-986446 as Cobenfy drives early sales and pipeline momentum.

13 days ago - Nasdaq